Patterns of clozapine prescribing in a mental health service in New Zealand

Pharmacy World and Science

Volumn 32, Issue 4, 2010, Pages 503-511

  Harrison, Jeff ^a,c   Janlöv, Minna ^b   Wheeler, Amanda J ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UPPSALA UNIVERSITY   (Sweden)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Clinical audit; Clozapine; Guidelines; New Zealand; Prescribing; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; FUNDING; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL RECORD; MENTAL HEALTH SERVICE; NEW ZEALAND; OCCUPATION; OUTPATIENT DEPARTMENT; PRESCRIPTION; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMMUNITY MENTAL HEALTH SERVICES; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 77956418967     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9398-5     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders fourth edition. Washington DC: American Psychiatric Association; 1994.
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington DC: American Psychiatric Association; 2004.
3. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders. Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005;39(1-2):1-30.
4. National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment of schizophrenia in primary and secondary care. Clinical guideline 1. London: National Institute for Clinical Excellence; 2002.
5. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 9657 31 41 10.1016/S0140-6736(08)61764-X 1:CAS:528: DC%2BD1MXht1Wqsw%3D%3D 19058842
6. S Hiltgen S Mantelet F Pinabel F Enjaume 2006 Retrospective study of clozapine use in Ile-de-France E?tude re?trospective sur l'utilisation de la clozapine en I?le-de-France 32 5 I 688 696 1:STN:280:DC%2BD28nmt1GmsQ%3D%3D
7. J Kane G Honigfeld J Singer H Meltzer 1988 Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Arch Gen Psychiatry 45 9 789 796 1:STN:280:DyaL1czisFyisQ%3D%3D 3046553
8. JM Kane SR Marder NR Schooler WC Wirshing D Umbricht RW Baker, et al. 2001 Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison Arch Gen Psychiatry 58 10 965 972 10.1001/archpsyc.58.10.965 1:CAS:528:DC%2BD3MXnvVCru7Y%3D 11576036
9. SW Lewis TRE Barnes L Davies RM Murray G Dunn KP Hayhurst, et al. 2006 Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia Schizophr Bull 32 4 715 723 10.1093/schbul/sbj067 16540702 (Pubitemid 44412859)
10. JP McEvoy JA Lieberman TS Stroup SM Davis HY Meltzer RA Rosenheck, et al. 2006 Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment Am J Psychiatry 163 4 600 610 10.1176/appi.ajp.163.4.600 16585434 (Pubitemid 44464569)
11. DC Henderson DD Nguyen PM Copeland DL Hayden CP Borba PM Louie, et al. 2005 Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study J Clin Psychiatry 66 9 1116 1121 10.4088/JCP.v66n0905 1:CAS:528:DC%2BD2MXhtFequrjP 16187768
12. A Safferman JA Lieberman JM Kane S Szymanski B Kinon 1991 Update on the clinical efficacy and side effects of clozapine Schizophr Bull 17 2 247 261 1:STN:280:DyaK3Mzlt1GltA%3D%3D 1882209
13. Novartis New Zealand Ltd. CLOZARIL® Data Sheet. Wellington, New Zealand: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 June 2009; cited 14/12/2009]. http://www.medsafe.govt.nz/ profs/Datasheet/c/Clozariltab.htm.
14. Douglas Pharmaceuticals Ltd. CLOPINE® Data Sheet. Wellington, New Zealand.: Medsafe (New Zealand Medicines and Medical Devices Safety Authority); 2009 [updated 2009 December 2008; cited 14/12/2009]. http://www.medsafe.govt.nz/ profs/datasheet/c/Clopinetab.htm.
15. I Melle TK Larsen U Haahr S Friis JO Johannessen S Opjordsmoen, et al. 2004 Reducing the duration of untreated first-episode psychosis: effects on clinical presentation Arch Gen Psychiatry 61 2 143 150 10.1001/archpsyc.61.2.143 14757590 (Pubitemid 38146548)
16. W Gaebel S Weinmann N Sartorius W Rutz JS McIntyre 2005 Schizophrenia practice guidelines: international survey and comparison Br J Psychiatry 187 3 248 255 10.1192/bjp.187.3.248 16135862 (Pubitemid 41306106)
17. National Institute for Clinical Excellence (NICE) Guidelines in the UK. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care National Institute for Clinical Excellence (NICE) guidelines in the UK. 2002. p. 1-264.
18. Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(13):7S-57S.
19. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. J Clin Psychiatry. 2003;64(Suppl 12):2-97.
20. AF Lehman J Kreyenbuhl RW Buchanan FB Dickerson LB Dixon R Goldberg, et al. 2004 The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003 Schizophr Bull 30 2 193 217 15279040
21. AL Miller CS Hall RW Buchanan PF Buckley JA Chiles RR Conley, et al. 2004 The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update J Clin Psychiatry 65 4 500 508 10.4088/JCP.v65n0408 15119912
22. Walker RA, Martin S. Demographic profile for Waitemata District health board: an analysis of 2006 census. Auckland: Watemata District Health Board; 2007.
23. Bailey D. A users guide to the Mental Health (Compulsory Assessment and Treatment) Act. Wellington: Department of Health; 1992.
24. RJ Baldessarini BM Cohen MH Teicher 1988 Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses Arch Gen Psychiatry 45 1 79 91 1:CAS:528:DyaL1cXoslCjsQ%3D%3D 2892478
25. R Ganguly JA Kotzan LS Miller K Kennedy BC Martin 2004 Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000 J Clin Psychiatry 65 10 1377 1388 10.4088/JCP.v65n1013 15491242
26. YT Xiang YZ Weng CM Leung WK Tang GS Ungvari 2007 Clinical correlates of clozapine prescription for schizophrenia in China Hum Psychopharmacol 22 1 17 25 10.1002/hup.821 1:CAS:528:DC%2BD2sXisVKgtbg%3D 17191268 (Pubitemid 46178774)
27. XS Ren LE Kazis AF Lee A Hamed 2002 Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia J Clin Pharm Therapeut 27 441 451 10.1046/j.1365-2710.2002.00443.x 1:STN:280:DC%2BD3s%2FhtVSjsA%3D%3D (Pubitemid 35463897)
28. A Wheeler 2007 Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders Aust N Z J Psychiatry 41 10 809 818 10.1080/00048670701579066 17828654 (Pubitemid 47399959)
29. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861-7.
30. S Leucht T Burkard J Henderson M Maj N Sartorius 2007 Physical illness and schizophrenia: a review of the literature Acta Psychiatr Scand 116 5 317 333 10.1111/j.1600-0447.2007.01095.x 1:STN:280:DC%2BD2srpvFWrsQ%3D%3D 17919153 (Pubitemid 47537428)
31. J Sokal E Messias FB Dickerson J Kreyenbuhl CH Brown RW Goldberg, et al. 2004 Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services J Nerv Ment Dis 192 6 421 427 10.1097/01.nmd.0000130135.78017.96 15167405 (Pubitemid 38746100)
32. DM Taylor C Young C Paton 2003 Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review J Clin Psychiatry 64 1 30 34 10.4088/JCP.v64n0107 12590620
33. WJ Broekman IW de Groot PN van Harten 2007 Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study Pharm World Sci 29 126 1230 10.1007/s11096-006-9063-1 (Pubitemid 46872979)
34. A McKean J Vella-Brincat E Begg 2008 Prescribing and monitoring clozapine in Christchurch Aust Psychiatry 16 4 263 267 10.1080/10398560802189896
35. Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv. 2005;56(3):320-3.
36. O Agid G Remington S Kapur T Arenovich RB Zipursky 2007 Early use of clozapine for poorly responding first-episode psychosis J Clin Psychopharmacol 27 4 369 373 10.1097/jcp.0b013e3180d0a6d4 1:CAS:528:DC%2BD2sXns1Cmt70%3D 17632221 (Pubitemid 47075508)
37. R Kerwin 2007 When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine CNS Drugs 21 4 267 278 10.2165/00023210-200721040-00002 1:CAS:528:DC%2BD2sXmtVyrs7g%3D 17381182 (Pubitemid 46598448)